[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthroplasty-replacement-hip\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthroplasty-replacement-hip":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,86,122,142,169,205,226,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644790","multimodal-analgesic-regimen-for-total-hip-arthroplasty-an-initiative-to-minimize-postoperative-opioid-use-100644790",false,"NCT07672808","Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use","Inclusion Criteria:\n\n* Adult patients age 18 and older\n* Patients who have undergone total hip arthroplasty by a single, fellowship trained Orthopaedic Surgeon.\n\nExclusion Criteria:\n\n* Patients with incomplete data in medical records\n* Chronic opioid use in the last 3 months\n* Ipsilateral joint surgery in the last year\n* Cannot tolerate oral medications\n* Swallowing difficulties\n* Intolerance to Tylenol, Celebrex, Robaxin, Neurontin, or Tramadol\n* History of Alcohol abuse\n* History of Drug abuse\n* History of Renal impairment\n* History of Peptic ulcer disease\n* History of GI bleeding\n* Illicit narcotic usage in past 6 months\n* Chronic liver disease\n* Chronic pain syndrome","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study examines whether patients undergoing total hip replacement surgery can manage their pain effectively while using fewer opioid pain medications. Participants will be randomly assigned to one of two groups. The first group will receive the standard postoperative pain medication regimen, with all prescriptions sent directly to their pharmacy as usual. The second group will receive the same medications, but their opioid prescription will only be provided as a printed copy rather than being sent directly to the pharmacy, requiring them to choose whether to fill it. All participants will keep a pain journal and complete questionnaires about their medication intake over the first 21 days post-op as well as there function and wellbeing at follow up visits over 3 months. The goal is to determine whether this approach reduces opioid use while still adequately controlling pain after hip replacement surgery.",[25],"Arthroplasty, Replacement, Hip",[27,28,29,30,31,32,33,34,35,36],"Total hip arthroplasty","Hip replacement","Opioid","Postoperative pain","Multimodal analgesia","Tramadol","Pain management","Opioid reduction","Patient reported outcomes","Orthopedic Surgery","NOT_YET_RECRUITING","2026-06-22",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":19},"2026-06-01",{"date":45,"type":19},"2027-05-30",{"name":47,"class":48},"Henry Ford Health System","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":20,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":49},"100641421","preoperative-fasting-and-the-gut-microbiome-before-hip-replacement-100641421","NCT07651462","Preoperative Fasting and the Gut Microbiome Before Hip Replacement","Preoperative Metabolic Optimization: Influence of Intermittent and Buchinger-Type Fasting on the Gut Microbiome, Immune Profile, and Postoperative Complications in Patients Undergoing Primary Total Hip Arthroplasty - A Randomized Controlled Trial","PreFAST-Hip","Inclusion Criteria:\n\n* Adults aged 18-75 years (inclusive)\n* Scheduled for elective primary total hip arthroplasty (THA)\n* Able and willing to provide written informed consent\n* Able to follow the 20-day preoperative fasting protocol independently at home (if randomized to the fasting arm) or willing to be randomized to either arm\n\nExclusion Criteria:\n\n* Resorption disorder due to bowel disease (e.g. inflammatory bowel disease, short-bowel syndrome, active celiac disease)\n* Antibiotic therapy within the last 2 months before baseline (T0)\n* Probiotic, prebiotic, or symbiotic supplementation within the last 2 months before baseline (T0)\n* Inability or unwillingness to provide informed consent\n* Severe comorbidity precluding fasting (e.g. ASA ≥ IV, advanced renal\u002Fhepatic impairment, eating disorder)\n* BMI \\\u003C 18.5 kg\u002Fm² (underweight)\n* Concurrent participation in another interventional drug or device trial\n* Pregnancy or breastfeeding","75 Years",{"count":60,"type":19},130,[22],"Postoperative complications occur in 5-15% of patients undergoing elective primary total hip arthroplasty (THA), including periprosthetic joint infection (PJI), thrombosis, wound healing disorders, and metabolic dysregulation. The gut microbiome and the systemic immune profile have both been implicated as modifiable contributors to perioperative complication risk. Preoperative therapeutic fasting has been shown to remodel the gut microbiome, lower proinflammatory cytokines, and improve metabolic parameters.\n\nThis single-center, prospective, randomized, two-arm controlled trial at Charité - Universitätsmedizin Berlin investigates whether a structured 20-day preoperative fasting intervention (alternating cycles of the Buchinger Fastenbox and intermittent fasting) modulates two co-primary endpoints - plasma IL-8 (a central proinflammatory marker) and gut microbial alpha-diversity (Shannon index) - compared with standard preoperative care. Secondary endpoints include further immune markers (TNFα, IL-10, T-\u002FB-\u002FNK-cell subsets, activation\u002Fexhaustion markers, monocyte HLA-DR), microbiome composition and function, continuous glucose-monitoring and daily metabolic measures, patient-reported outcomes (HOOS, PROMIS-33, infection self-report), and clinical outcomes (postoperative complications per EBJIS criteria, length of stay).\n\nAdults aged 18-75 undergoing elective primary THA are stratified by metabolic status (metabolically healthy vs. metabolically unhealthy according to harmonized metabolic-syndrome criteria) and randomized 1:1 to the fasting intervention versus standard care. Stool and whole-blood samples are collected at baseline (Day -21), and at Day +7 post-operatively for shotgun-metagenomic sequencing and multiparameter flow cytometry, with additional cytokine blood samples at Day -1 and 6 h \u002F 24 h \u002F 72 h post-operatively. Continuous glucose monitoring is performed in all participants from Day -21 until surgery. Planned enrollment is 130 participants.",[64,25,65,66,67],"Hip Osteoarthritis","Postoperative Complications","Surgical Wound Infection","Gastrointestinal Microbiome",[69,70,71,72,73,74,27,75,76],"Therapeutic fasting","Buchinger fasting","Intermittent fasting","Gut microbiome","Immunophenotyping","Continuous glucose monitoring","Metabolic syndrome","Preoperative optimization","RECRUITING","2026-06-17",{"date":38,"type":41},{"date":81,"type":41},"2025-07-01",{"date":83,"type":19},"2026-12-31",{"name":85,"class":48},"Charite University, Berlin, Germany",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":49},"100611379","peng-block--lia-for-endoprosthesis-surgery-100611379","NCT07239817","PENG Block + LIA For Endoprosthesis Surgery","PENG 360°: PENG Block + LIA Nella Endoprotesi di Anca.","PENG 360°","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Scheduled for hip endoprosthesis surgery for femoral fracture with an anterior approach.\n* Age 18 years or older.\n* Willing and able to comply with the study protocol.\n\nExclusion Criteria:\n\n* Failure to provide informed consent.\n* Age less than 18 years.\n* Known allergy to local anesthetics or other medications used in the protocol.\n* Presence of infection at the planned injection site.\n* Pre-existing hip prosthesis or prior major surgery on the same hip (e.g., revision surgery).\n* ASA physical status class \\> IV.\n* Administration of intraoperative opiates or conversion to general anesthesia.",{"count":18,"type":19},[22],"The goal of this clinical trial is to learn if a new local anesthesia technique can control pain as well as the standard spinal anesthesia for adults having hip endoprosthesis surgery. The main questions it aims to answer are:\n\n* Is the new local anesthesia technique as effective as standard spinal anesthesia in managing pain during the first two days after surgery?\n* Does the new technique allow participants to move their leg sooner after the operation?\n\nResearchers will compare the new local anesthesia technique (numbing medicine injected directly around the hip joint) to standard spinal anesthesia (a numbing injection in the back) to see if the new technique works just as well for pain control while possibly causing fewer side effects like nausea.\n\nParticipants who join this study will be randomly placed into one of two groups.\n\nOne group will receive the standard spinal anesthesia before their surgery.\n\nThe other group will receive the new local anesthesia technique before their surgery.\n\nAfter the operation, researchers will track the amount of extra pain medicine each participant uses and will check their ability to move their hip, knee, and foot.",[98,25,99,100,101,102],"Hip Fractures","Pain, Postoperative","Anesthesia and Analgesia","Nerve Block","Local Anesthesia Infiltration",[104,105,106,107,108,109,110,111,112],"Pericapsular Nerve Group Block","PENG block","Local Infiltration Analgesia","Spinal Anesthesia","Hip Arthroplasty","Postoperative Pain","Femoral Fractures","Ultrasound Guidance","Early Mobilization","2026-06-10",{"date":115,"type":41},"2026-06-12",{"date":117,"type":41},"2025-12-09",{"date":119,"type":19},"2026-12-30",{"name":121,"class":48},"ASST Gaetano Pini-CTO",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":49},"100431346","sleep-patterns-after-total-joint-replacement-surgery-100431346","NCT04896892","Sleep Patterns After Total Joint Replacement Surgery","Inclusion Criteria:\n\n* Patient is to undergo ambulatory total hip arthroplasty or total hip knee arthroplasty.\n* Patient is 18 years or older.\n\nExclusion Criteria:\n\n* Patient is unable to give consent\n* Non-English speaking patients\n* Patients with pre-existing sleep disorders or neurological disorders, including dementia.\n* Patients taking hypnotic drugs or other medication that is known to affect sleep.",true,{"count":130,"type":19},60,"OBSERVATIONAL","The purpose of this study is to determine sleep patterns and sleep quality following total joint arthroplasty, in order to understand when patients should expect to return to baseline or improved sleep following total joint arthroplasty. Patients prospectively enrolled in this study are to undergo total knee arthroplasty (TKA) or total hip arthroplasty (THA). Patients will receive the SleepScore Max device and smart device app to track their sleep patterns starting one week prior to surgery and until six months after surgery. The SleepScore Max device tracks duration of sleep, time to fall asleep, number of nightly awakenings, rapid eye movement sleep, light sleep, deep sleep, and room temperature and light levels. Through the associated application, patients will also record caffeine and alcohol consumption and exercise. In addition to sleep tracking, patients will fill out Pittsburgh Sleep Quality Index (PSQI), PROMIS, Hip Disability and Osteoarthritis Outcome Score (HOOS), and Knee Injury and Osteoarthritis Outcome Score (KOOS) surveys at specified visits. Secondarily, Visual Analog Pain (VAP) scores and opioid consumption measure in milligram morphine equivalents (MME) will be measured during hospital stay and at subsequent post-operative clinic visits. The clinical goal of this study is to better under sleep patterns in patients undergoing TKA and THA and hopefully provide this patient population improved sleep recommendations and interventions.",[134,25],"Arthroplasty, Replacement, Knee","2026-04-29",{"date":137,"type":41},"2026-05-05",{"date":43,"type":19},{"date":140,"type":19},"2028-03-01",{"name":47,"class":48},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":20,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":49},"100484806","a-study-of-the-effect-of-a-nurse-navigator-program-on-high-risk-patients-100484806","NCT05592847","A Study of the Effect of a Nurse Navigator Program on High Risk Patients","The Effect of a Nurse Navigator Program on Readmission Rates for Patients With Elevated BMI, COPD, CHF, Dialysis Use, and H\u002Fo Alcohol Abuse","Inclusion Criteria:\n\n\\- Require total or partial hip or knee replacement and have one or more of the following diagnosis: Heart Failure (HF); Chronic obstructive pulmonary disease (COPD); Dialysis; Alcohol Abuse; Low BMI.\n\nExclusion Criteria:\n\n\\- Decrease cognitive capacity to consent to the study.",{"count":150,"type":19},300,[22],"The purpose of this study is to examine if educational intervention in high risk patients can lead to decreased hospital readmissions when compared to patients who are not in the intervention program. Additionally, to determine patient satisfaction with the educational program.",[154,134,25,155,156,157,158,159],"Patient Readmission","Heart Failure","Pulmonary Disease, Chronic Obstructive","Renal Insufficiency","Body Mass Index","Alcoholism","2026-03-17",{"date":162,"type":41},"2026-03-19",{"date":164,"type":19},"2027-01",{"date":166,"type":19},"2027-06",{"name":168,"class":48},"Mayo Clinic",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":20,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":49},"100619490","development-and-measurement-of-the-effects-of-a-digital-education-solution-for-patients-undergoing-total-hip-or-knee-arthroplasty-100619490","NCT07345299","Development and Measurement of the Effects of a Digital Education Solution for Patients Undergoing Total Hip or Knee Arthroplasty","CHUVeduc@home","Inclusion Criteria:\n\n* male and female patients admitted to the CHUV musculoskeletal department during the study period\n* primary total hip replacement or primary total knee replacement\n* a Risk Assessment and Prediction Tool (RAPT) score \\>6\n\nExclusion Criteria:\n\n* a RAPT score \\\u003C6,\n* knee\u002Fhip arthroplasty revision surgery\n* inability to give informed consent or answer questionnaires knowledgeably due to language or cognitive impairment as reported in the medical record",{"count":177,"type":19},160,[22],"This study aims to evaluate the effectiveness of a digital patient education solution, CHUVeduc@home, in improving preoperative preparation for patients undergoing total hip or knee arthroplasty. In Switzerland, many patients receive joint replacements each year to relieve osteoarthritis-related pain. With shorter hospital stays, adequate preparation before surgery has become increasingly important.\n\nA total of 160 patients will be randomized into two groups:\n\nIntervention group: access to CHUVeduc@home before surgery. Control group: standard preoperative preparation (group information session and consultation).\n\nAll participants will complete questionnaires through the application. No additional visits are required. The intervention lasts approximately 12 weeks.\n\nThe primary goal is to determine whether digital education increases patient knowledge, confidence, and satisfaction, and facilitates recovery and return home after surgery. Participation is voluntary and can be withdrawn at any time.",[181,25],"Arthroplasty Replacement, Knee",[183,184,185,186,187,188,189,190,191,192,193,194,195],"knee","hip","replacement","arthroplasty","patient education","digital solution","preoperative care","perioperative care","interdisciplinary intervention","physiotherapy","nursing","health literacy","digital literacy","2026-01-09",{"date":198,"type":41},"2026-01-15",{"date":200,"type":19},"2026-02-15",{"date":202,"type":19},"2027-02-28",{"name":204,"class":48},"Haute Ecole de Santé Vaud",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":49},"100603146","associations-between-time-to-reduction-and-complications-in-patients-with-dislocated-total-hip-arthroplasty-100603146","NCT07132723","Associations Between Time to Reduction and Complications in Patients With Dislocated Total Hip Arthroplasty","Associations Between Time to Reduction and Complications in Patients With Dislocated Total Hip Arthroplasty - A Protocol for an Observational Cohort Study","Inclusion Criteria:\n\nPatients will be considered eligible for inclusion if they meet all of the following criteria:\n\n* Aged 18 years or older\n* Presented to the emergency department with a dislocated total hip arthroplasty.\n* Undergo closed reduction of the dislocated total hip arthroplasty in the operating theatre, with the involvement of the Department of Anesthesiology.\n\nExclusion Criteria:\n\n* Were primarily booked for open surgical reduction.\n* Did not have a complete case log (i.e. time of admission; referral to the operation theatre; anesthesia induction; discharge, etc.) and we were unable to recreate the log using simple code rules.",{"count":213,"type":19},3700,"The aim of the study is to investigate the impact of time to closed reduction on both patient related and organizational factors. These include, length of stay, hospitalization, admission to intensive care unit, rehospitalizations, delirium, all-cause mortality, infection requiring hospital contact, and cardiovascular complications. It is also intended to investigate whether different anaesthetic strategies and airway management are associated with different complication rates.\n\nIt is hypothesized that longer waiting time until reduction increase the postoperative length of stay, readmissions, and risk of complications.",[216,25,217],"Closed Reduction","Length of Stay","2025-08-11",{"date":220,"type":41},"2025-08-20",{"date":220,"type":19},{"date":223,"type":19},"2025-10-01",{"name":225,"class":48},"Nordsjaellands Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":20,"phases":236,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":49},"100452263","phase-2-antibiotic-impregnated-bone-graft-to-reduce-infection-in-hip-replacement-100452263","NCT05169229","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial","ABOGRAFT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hip arthroplasty requiring bone graft\n3. Willing to provide informed consent.\n4. For women of childbearing potential; a negative pregnancy test prior to reoperation.\n\nExclusion Criteria:\n\n1. Ongoing prosthetic joint infection\n2. Known allergies and contraindications for the use of vancomycin or tobramycin\n3. Mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation\n4. Expected difficulties to complete 2-year follow-up\n5. Females of child bearing potential not using contraception\n6. Pregnant females\n7. Nursing females",{"count":235,"type":19},1100,[237,238],"PHASE2","PHASE3","Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities.\n\nThe number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent.\n\nImpacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.",[25,241,242,243],"Osteoarthritis, Hip","Antibiotic Resistant Infection","Prosthetic Joint Infection","2025-07-17",{"date":246,"type":41},"2025-07-22",{"date":248,"type":41},"2022-04-01",{"date":250,"type":19},"2031-12",{"name":252,"class":48},"University Hospital, Linkoeping",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":20,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":49},"100593553","phase-2-phase-iia-trial-of-oral-sss17-for-post-arthroplasty-anemia-100593553","NCT07007936","Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate the Efficacy and Safety of Oral SSS17 Capsules in the Treatment of Anemia Following Total Hip or Knee Arthroplasty","Inclusion Criteria:\n\n1. Signed informed consent obtained\n\n   \\-\n2. Age 18-70 years (inclusive)\n\n   \\-\n3. Candidates for hip\u002Fknee arthroplasty\n\n   \\-\n4. No DVT on pre-op venous ultrasound\n\n   \\-\n5. Screening Hb 80-110 g\u002FL (no transfusion indication) - 6. Commitment to effective contraception\n\nExclusion Criteria:\n\n1. Hypersensitivity to the investigational product or any of its components\n2. Any other condition causing chronic anemia\n3. Coagulopathy or unstable anticoagulant dosing during screening\n4. Any of the following laboratory abnormalities at screening:\n\n   1. Serum albumin \\\u003C35 g\u002FL\n   2. ALT or AST \\>3×ULN\n5. Active infections or carrier status including:\n\n   * Known HIV infection\n   * Active syphilis\n   * Active HBV infection (HBsAg-positive with HBV DNA \\>10³ copies\u002FmL)\n   * Active HCV infection (anti-HCV positive with detectable HCV RNA)\n6. Acute joint injury with active trauma or infection at screening\n7. Cognitive impairment or psychiatric disorders,current or history of epilepsy\n8. Treatment with ESAs (erythropoiesis-stimulating agents) or HIF inhibitors within 30 days prior to dosing\n9. History of severe thromboembolic events or hematopoietic disorders\n10. Malignancy history\n11. Severe cardiovascular diseases including:\n\n    * Unstable coronary artery disease\n    * Heart failure (NYHA Class III\u002FIV)\n    * Myocardial infarction\u002Fstroke 12 .Poorly controlled hypertension\n\n13\\. Alcohol abuse 14.Pregnancy or lactation 15.Participation in other drug trials within 3 months prior to enrollment 16.Any other condition deemed by the Investigator to compromise subject safety or trial validity","70 Years",{"count":262,"type":19},90,[237],"To assess the safety, tolerability, efficacy, and pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.",[266,25,134],"Postoperative Anemia","2025-06-06",{"date":269,"type":41},"2025-06-11",{"date":271,"type":19},"2025-07",{"date":273,"type":19},"2026-04",{"name":275,"class":276},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY"]